Abstract 4179
Background
Validated serum biomarkers for patients suffering from non-small cell lung cancer (NSCLC) brain metastasis are urgently needed for early diagnosis, treatment monitoring, and prognostic classification in daily clinical practice and trials. Serum S100B was reported to be a marker of leaky blood-brain barrier (BBB), which was often caused by brain tumors. This study aimed to investigate the role of S100B and S100B antibody in the early detection of NSCLC brain metastasis and the prognostic significance.
Methods
100 patients with NSCLC brain metastasis, 50 patients of stage IV NSCLC without brain metastasis, and 50 patients with cerebrovascular diseases were enrolled in this prospective study. S100B and S100B antibody were measured in serum samples of all patients before and after treatment by ELISA, and the correlations with brain metastasis were assessed by ANOVA. Kaplan-Meier survival analyses and COX regression were used to unveil the prognosis significance.
Results
The results showed that serum S100B correlated significantly with NSCLC brain metastasis (p < 0.001), but not S100B antibody (p > 0.05). When evaluated by the ROC curve, at the cutoff point 13.83 pg/ml, the sensitivity and specificity were 94% and 93%, respectively (AUC= 0.938, p < 0.001). The PFS and OS of NSCLC patients with brain metastasis were significantly shorter in the patients with high levels of serum S100B. In addition, S100B was an independent prognostic factor.
Conclusions
In conclusion, serum S100B was a sensitive and specific marker for early detection of brain metastasis in NSCLC and could be used as a surveillance tool for prognosis evaluation.
Clinical trial identification
Legal entity responsible for the study
Affiliated Cancer Hospital of Zhengzhou University.
Funding
Has not received any funding.
Editorial Acknowledgement
We thank Bart's Cancer Institute, Queen Mary University of London for supporting our work.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
6106 - Multi-Dimensional Immuno-Oncology Assays for Understanding the Immune System and Tumor Microenvironment
Presenter: Fiona Hyland
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5045 - Monitoring the effect of PI3K inhibition on HER2 therapy resistant breast cancer using serial analysis of PIK3CA mutant tumour DNA in plasma
Presenter: Niamh Keegan
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5653 - Analysis of circulating biomarkers in A randomized phase II trial of maintenance oral metronomic vinorelbine in advanced NSCLC following platinum-based chemotherapy: A correlative MA.NI.LA. trial study
Presenter: Mattia Boeri
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5663 - Oral cavity immune response in pancreatic ductal adenocarcinoma (PDAC)
Presenter: Juan Marquez
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5029 - Tumor Mutational Burden (TMB) Standardization Initiative: Establishing a Consistent Methodology for TMB Measurement in Clinical Samples
Presenter: Albrecht Stenzinger
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4563 - DNA damaging agents and immunotherapy in NSCLC: Is there a STING in the tale?
Presenter: Carminia Maria Della Corte
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1612 - Tumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT)
Presenter: Juan Martin-Liberal
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3960 - Cyclin D1 differential activation and its prognostic impact among advanced breast cancer patients treated with trastuzumab.
Presenter: Giannis Mountzios
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4272 - Expression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical response to CDK4/6 inhibitors in breast cancer
Presenter: Stefania Crucitta
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4940 - HER2 amplification is associated with higher tumor mutation burden in breast cancer
Presenter: Yongmei Yin
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract